Alluvi, formerly BI 4744, offers a promising advance in obesity therapy. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/